Overview
This is an observational and non-interventional clinical study that only collects long-term follow-up data of the subjects. As the world's first approved PD-1/CTLA-4 bispecific antibody for marketing, Cadonilimab may confer long-term survival benefits.
Eligibility
Inclusion Criteria:
- Ability to understand and voluntarily sign a written informed consent form (ICF), which must be signed before the specified study procedures required for the study are performed.
- Subjects have received prior systemic therapy in sponsor-initiated clinical trials of cadonilimab (AK104), and this extension study is conducted after the completion of the original trial.
- Agree to proceed with the extended follow-up procedures.
- This is an observational and non-interventional clinical study, in which subjects are allowed to participate in other clinical studies at the same time.
Exclusion Criteria:
- None
